Tsutsui Anna, Murakami Yoshitaka, Nishiwaki Yuji, Asakura Keiko, Ohfuji Satoko, Fukushima Wakaba, Matsuoka Katsuyoshi, Hisamatsu Tadakazu
Department of Medical Statistics, School of Medicine, Toho University, 5-21-16 Omori-Nishi, Ota-Ku, Tokyo, 143-8540, Japan.
Department of Environmental and Occupational Health, School of Medicine, Toho University, Tokyo, Japan.
J Gastroenterol. 2025 Sep 2. doi: 10.1007/s00535-025-02295-z.
BACKGROUND: Almost a decade has passed since the previous nationwide survey on the prevalence of ulcerative colitis (UC) and Crohn's disease (CD) in Japan was conducted in 2015. We conducted a new nationwide hospital-based survey to provide updated estimates of the patient numbers and prevalence rates of UC and CD in Japan in 2023. METHODS: Stratified random sampling was used to select hospital departments (internal medicine, surgery, pediatrics, and pediatric surgery) that routinely treat UC and CD patients. We sent questionnaires to the sampled departments to request sex-specific information on their patient numbers for UC and CD in 2023. Based on the responses, we estimated the annual patient numbers and prevalence rates of UC and CD throughout Japan. The estimates were compared with those from the previous 2015 survey. RESULTS: The overall survey response rate was 50.8% (1,798/3,538 departments). The estimated patient numbers were approximately 316,900 (95% confidence interval: 223,900-409,900) for UC and 95,700 (61,100-130,400) for CD, both of which represent a 1.4-fold increase over the 8-year period since 2015. The annual prevalence rates per 100,000 population were 254.8 (male: 297.5; female: 214.4) for UC and 77.0 (male: 112.9, female: 43.0) for CD. The male-to-female ratios were 1.31 for UC and 2.49 for CD, and the UC-to-CD ratio was 3.31. CONCLUSIONS: The patient numbers and prevalence rates of UC and CD have continued to steadily increase in Japan, suggesting the need for continued monitoring and further investigation to track the disease burden.
背景：自上次2015年在日本进行全国性溃疡性结肠炎（UC）和克罗恩病（CD）患病率调查以来，已过去近十年。我们开展了一项新的基于全国医院的调查，以提供2023年日本UC和CD患者数量及患病率的最新估计。 方法：采用分层随机抽样法选择常规治疗UC和CD患者的医院科室（内科、外科、儿科和小儿外科）。我们向抽样科室发送问卷，以获取2023年其UC和CD患者按性别分类的信息。根据回复，我们估计了全日本UC和CD的年度患者数量及患病率。将这些估计值与2015年上次调查的结果进行比较。 结果：总体调查回复率为50.8%（1798/3538个科室）。UC的估计患者数量约为316,900（95%置信区间：223,900 - 409,900），CD为95,700（61,100 - 130,400），自2015年以来的8年期间两者均增长了1.4倍。每10万人口的年度患病率，UC为254.8（男性：297.5；女性：214.4），CD为77.0（男性：112.9，女性：43.0）。UC的男女比例为1.31，CD为2.49，UC与CD的比例为3.31。 结论：在日本，UC和CD的患者数量及患病率持续稳步上升，这表明需要持续监测并进一步开展调查以追踪疾病负担。
Cochrane Database Syst Rev. 2014-1-20
Cochrane Database Syst Rev. 2021-11-29
Therap Adv Gastroenterol. 2025-8-18
Int J Colorectal Dis. 2023-5-19
Zotero 插件